166 related articles for article (PubMed ID: 6823373)
21. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma.
Kühnel R; Delemarre JF; Rao BR; Stolk JG
Anticancer Res; 1986; 6(5):889-92. PubMed ID: 3026234
[TBL] [Abstract][Full Text] [Related]
22. [Estrogen and progesterone receptors in ovarian carcinoma].
Kanajet D; Klarić P; Bolf-Benković L
Jugosl Ginekol Perinatol; 1985; 25(1-2):13-6. PubMed ID: 3003465
[TBL] [Abstract][Full Text] [Related]
23. [Localization of sex steroid hormone and sex steroid hormone receptors in human ovarian epithelial tumor].
Ino Y; Takizawa K; Sato M; Yokoo I; Iguchi T; Takeda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Jan; 42(1):9-15. PubMed ID: 2299246
[TBL] [Abstract][Full Text] [Related]
24. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
[TBL] [Abstract][Full Text] [Related]
25. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Geisler JP; Wiemann MC; Miller GA; Geisler HE
Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
[TBL] [Abstract][Full Text] [Related]
26. Estrogen and progesterone receptors in ovarian epithelial tumors.
Lindgren PR; Cajander S; Bäckström T; Gustafsson JA; Mäkelä S; Olofsson JI
Mol Cell Endocrinol; 2004 Jun; 221(1-2):97-104. PubMed ID: 15223136
[TBL] [Abstract][Full Text] [Related]
27. [Cytosol receptor levels in malignant and benign ovarian tumors].
Thurzó L; Falkay G; Sas M
Orv Hetil; 1987 Aug; 128(36):1881-4, 1887. PubMed ID: 3658406
[No Abstract] [Full Text] [Related]
28. Female sex steroid receptors in gynecological malignancies: clinical correlates.
Vihko R; Isotalo H; Kauppila A; Vierikko P
J Steroid Biochem; 1983 Jul; 19(1C):827-32. PubMed ID: 6887902
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
30. Estrogen and progestin binding in cytosols of ovarian adenocarcinomas.
Holt JA; Caputo TA; Kelly KM; Greenwald P; Chorost S
Obstet Gynecol; 1979 Jan; 53(1):50-8. PubMed ID: 760018
[TBL] [Abstract][Full Text] [Related]
31. Relationship of presence of progesterone receptors to prognosis in early breast cancer.
Pichon MF; Pallud C; Brunet M; Milgrom E
Cancer Res; 1980 Sep; 40(9):3357-60. PubMed ID: 7427948
[TBL] [Abstract][Full Text] [Related]
32. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
Lazo JS; Schwartz PE; MacLusky NJ; Labaree DC; Eisenfeld AJ
Cancer Res; 1984 Jun; 44(6):2265-71. PubMed ID: 6722767
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
36. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
37. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and progesterone receptors in human ovarian tumors.
Willcocks D; Toppila M; Hudson CN; Tyler JP; Baird PJ; Eastman CJ
Gynecol Oncol; 1983 Oct; 16(2):246-53. PubMed ID: 6313494
[TBL] [Abstract][Full Text] [Related]
39. [Hormonal therapy of endometrial cancer].
Kato J
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1182-8. PubMed ID: 4057575
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma.
Villena-Heinsen C; Meyberg R; Axt-Fliedner R; Reitnauer K; Reichrath J; Friedrich M
Anticancer Res; 2002; 22(4):2261-7. PubMed ID: 12174912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
